LKB1 Represses ATOH1 via PDK4 and Energy Metabolism and Regulates Intestinal Stem Cell Fate.


Journal

Gastroenterology
ISSN: 1528-0012
Titre abrégé: Gastroenterology
Pays: United States
ID NLM: 0374630

Informations de publication

Date de publication:
04 2020
Historique:
received: 03 04 2019
revised: 02 12 2019
accepted: 30 12 2019
pubmed: 14 1 2020
medline: 11 7 2020
entrez: 14 1 2020
Statut: ppublish

Résumé

In addition to the Notch and Wnt signaling pathways, energy metabolism also regulates intestinal stem cell (ISC) function. Tumor suppressor and kinase STK11 (also called LKB1) regulates stem cells and cell metabolism. We investigated whether loss of LKB1 alters ISC homeostasis in mice. We deleted LKB1 from ISCs in mice using Lgr5-regulated CRE-ERT2 (Lkb1 Some intestinal crypts from Lkb1 LKB1 represses transcription of ATOH1, via PDK4, in ISCs, restricting their differentiation into secretory lineages. These findings provide a connection between metabolism and the fate determination of ISCs.

Sections du résumé

BACKGROUND & AIMS
In addition to the Notch and Wnt signaling pathways, energy metabolism also regulates intestinal stem cell (ISC) function. Tumor suppressor and kinase STK11 (also called LKB1) regulates stem cells and cell metabolism. We investigated whether loss of LKB1 alters ISC homeostasis in mice.
METHODS
We deleted LKB1 from ISCs in mice using Lgr5-regulated CRE-ERT2 (Lkb1
RESULTS
Some intestinal crypts from Lkb1
CONCLUSIONS
LKB1 represses transcription of ATOH1, via PDK4, in ISCs, restricting their differentiation into secretory lineages. These findings provide a connection between metabolism and the fate determination of ISCs.

Identifiants

pubmed: 31930988
pii: S0016-5085(20)30072-X
doi: 10.1053/j.gastro.2019.12.033
pii:
doi:

Substances chimiques

ATOH1 protein, human 0
Atoh1 protein, mouse 0
Basic Helix-Loop-Helix Transcription Factors 0
Pdk4 protein, mouse 0
Pyruvate Dehydrogenase Acetyl-Transferring Kinase 0
RNA, Messenger 0
RNA, Small Interfering 0
Dichloroacetic Acid 9LSH52S3LQ
Protein Serine-Threonine Kinases EC 2.7.11.1
STK11 protein, human EC 2.7.11.1
Stk11 protein, mouse EC 2.7.11.1
AMP-Activated Protein Kinase Kinases EC 2.7.11.3
AMP-Activated Protein Kinases EC 2.7.11.31
PRKAA1 protein, human EC 2.7.11.31

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1389-1401.e10

Informations de copyright

Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.

Auteurs

Yajing Gao (Y)

iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Finland; HiLIFE-Helsinki Institute of Life Science, University of Helsinki, Finland.

Yan Yan (Y)

iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Finland; HiLIFE-Helsinki Institute of Life Science, University of Helsinki, Finland. Electronic address: yany@mskcc.org.

Sushil Tripathi (S)

iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Finland; HiLIFE-Helsinki Institute of Life Science, University of Helsinki, Finland.

Nalle Pentinmikko (N)

iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Finland; HiLIFE-Helsinki Institute of Life Science, University of Helsinki, Finland; Institute of Biotechnology, HiLIFE, University of Helsinki, Finland.

Ana Amaral (A)

Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden.

Pekka Päivinen (P)

iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Finland; HiLIFE-Helsinki Institute of Life Science, University of Helsinki, Finland.

Eva Domènech-Moreno (E)

iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Finland; HiLIFE-Helsinki Institute of Life Science, University of Helsinki, Finland.

Simon Andersson (S)

iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Finland; HiLIFE-Helsinki Institute of Life Science, University of Helsinki, Finland; Institute of Biotechnology, HiLIFE, University of Helsinki, Finland.

Iris P L Wong (IPL)

iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Finland.

Hans Clevers (H)

Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and Cancer Genomics Netherlands, University Medical Center Utrecht and Princess Máxima Centre, Utrecht, The Netherlands.

Pekka Katajisto (P)

iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Finland; HiLIFE-Helsinki Institute of Life Science, University of Helsinki, Finland; Institute of Biotechnology, HiLIFE, University of Helsinki, Finland; Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden.

Tomi P Mäkelä (TP)

iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Finland; HiLIFE-Helsinki Institute of Life Science, University of Helsinki, Finland. Electronic address: tomi.makela@helsinki.fi.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH